Basic Tumor Immunology

Section edited by Cornelis J.M. Melief, MD, PhD

Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.

Previous Page Page 2 of 2 Next Page
  1. Research article

    NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade

    Melanoma is one of the few types of cancer with an increasing annual incidence. While a number of immunotherapies for melanoma have been associated with significant clinical benefit, including high-dose IL-2 a...

    Frederick J Kohlhapp, Joseph R Broucek, Tasha Hughes, Erica J Huelsmann, Jevgenijs Lusciks, Janet P Zayas, Hubert Dolubizno, Vidyaratna A Fleetwood, Alisa Grin, Graham E Hill, Joseph L Poshepny, Arman Nabatiyan, Carl E Ruby, Joshua D Snook, Jai S Rudra, Jason M Schenkel…

    Journal for ImmunoTherapy of Cancer 2015 3:18

    Published on: 19 May 2015

  2. Research article

    Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer

    Ovarian cancer is immunogenic and residual tumor volume after surgery is known to be prognostic. Ovarian cancer often follows a recurring-remitting course and microscopic disease states may present ideal oppor...

    John B Liao, Kelsie J Ovenell, Erin E M Curtis, Denise L Cecil, Marlese R Koehnlein, Lauren R Rastetter, Ekram A Gad and Mary L Disis

    Journal for ImmunoTherapy of Cancer 2015 3:16

    Published on: 19 May 2015

  3. Research article

    Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

    Multiple myeloma is characterized by the presence of transformed neoplastic plasma cells in the bone marrow and is generally considered to be an incurable disease. Successful treatments will likely require mul...

    Weiqing Jing, Jill A Gershan, James Weber, Dominique Tlomak, Laura McOlash, Catherine Sabatos-Peyton and Bryon D Johnson

    Journal for ImmunoTherapy of Cancer 2015 3:2

    Published on: 20 January 2015

  4. Research article

    T cell-NF-κB activation is required for tumor control in vivo

    T cells have the capacity to eliminate tumors but the signaling pathways by which they do so are incompletely understood. T cell priming requires activation of the transcription factors AP-1, NFAT and NF-κB do...

    Sarah E Barnes, Ying Wang, Luqiu Chen, Luciana L Molinero, Thomas F Gajewski, Cesar Evaristo and Maria-Luisa Alegre

    Journal for ImmunoTherapy of Cancer 2015 3:1

    Published on: 20 January 2015

  5. Research article

    iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine

    Therapeutic cancer vaccines aim to boost the natural immunity against transformed cancer cells, and a series of adjuvants and co-stimulatory molecules have been proposed to enhance the immune response against ...

    Stéphanie Corgnac, Rachel Perret, Lianjun Zhang, Jean-Pierre Mach, Pedro Romero and Alena Donda

    Journal for ImmunoTherapy of Cancer 2014 2:39

    Published on: 18 November 2014

  6. Research article

    Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes

    Invariant natural killer T (iNKT) cells are CD1d-restricted T cells, which respond rapidly to antigen recognition and promote development of anti-tumor immunity in many tumor models. Surprisingly, we previousl...

    Karsten A Pilones, Joseph Aryankalayil, James S Babb and Sandra Demaria

    Journal for ImmunoTherapy of Cancer 2014 2:37

    Published on: 14 October 2014

  7. Research article

    Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8+ T cells

    Several members of the common gamma chain (gc) cytokine family are already approved (IL-2) or actively being developed as vaccine adjuvants and cancer immunotherapies. Studies have indicated that co-administra...

    Michael J McNamara, Melissa J Kasiewicz, Stefanie N Linch, Christopher Dubay and William L Redmond

    Journal for ImmunoTherapy of Cancer 2014 2:28

    Published on: 16 September 2014

  8. Research article

    Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells

    The development of immunotherapy has led to significant progress in the treatment of metastatic cancer, including the development of genetic engineering technologies that redirect lymphocytes to recognize and ...

    Rachel E Beard, Zhili Zheng, Kiran H Lagisetty, William R Burns, Eric Tran, Stephen M Hewitt, Daniel Abate-Daga, Shannon F Rosati, Howard A Fine, Soldano Ferrone, Steven A Rosenberg and Richard A Morgan

    Journal for ImmunoTherapy of Cancer 2014 2:25

    Published on: 19 August 2014

  9. Research article

    The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma

    Indoleamine 2,3-dioxygenase (IDO) is an enzyme with immune-suppressive properties that is commonly exploited by tumors to evade immune destruction. Anti-tumor T cell responses can be initiated in solid tumors,...

    Minghui Li, Aaron R Bolduc, Md Nasrul Hoda, Denise N Gamble, Sarah-Bianca Dolisca, Anna K Bolduc, Kelly Hoang, Claire Ashley, David McCall, Amyn M Rojiani, Bernard L Maria, Olivier Rixe, Tobey J MacDonald, Peter S Heeger, Andrew L Mellor, David H Munn…

    Journal for ImmunoTherapy of Cancer 2014 2:21

    Published on: 7 July 2014

  10. Research article

    The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells

    Histone deacetylase (HDAC) inhibitors are a class of agents that have potent antitumor activity with a reported ability to upregulate MHC and costimulatory molecule expression. We hypothesized that epigenetic ...

    Dominique N Lisiero, Horacio Soto, Richard G Everson, Linda M Liau and Robert M Prins

    Journal for ImmunoTherapy of Cancer 2014 2:8

    Published on: 15 April 2014

  11. Research article

    Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells

    Myeloid-derived suppressor cells (MDSCs) are among the major obstacles that adjuvants for cancer vaccines have to overcome. These cells cross-present tumor-associated antigens (TAA) to naive T lymphocytes with...

    Audry Fernández, Liliana Oliver, Rydell Alvarez, Arletty Hernández, Judith Raymond, Luis E Fernández and Circe Mesa

    Journal for ImmunoTherapy of Cancer 2014 2:5

    Published on: 11 March 2014

  12. Research article

    Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

    Blockade of immune inhibitory pathways is emerging as an important therapeutic modality for the treatment of cancer. Single agent treatments have partial anti-tumor activity in preclinical models and in human ...

    Stefani Spranger, Holly K Koblish, Brendan Horton, Peggy A Scherle, Robert Newton and Thomas F Gajewski

    Journal for ImmunoTherapy of Cancer 2014 2:3

    Published on: 18 February 2014

  13. Research article

    Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells

    Sub-lethal doses of radiation can alter the phenotype of target tissue by modulating gene expression and making tumor cells more susceptible to T-cell-mediated immune attack. We have previously shown that sub-...

    Anita Kumari, Ercan Cacan, Susanna F Greer and Charlie Garnett-Benson

    Journal for ImmunoTherapy of Cancer 2013 1:17

    Published on: 23 September 2013

  14. Research article

    Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

    One of the significant tumor immune escape mechanisms and substantial barrier for successful immunotherapy is tumor-mediated inhibition of immune response through cell-to-cell or receptor/ligand interactions. ...

    Mikayel Mkrtichyan, Namju Chong, Rasha Abu Eid, Anu Wallecha, Reshma Singh, John Rothman and Samir N Khleif

    Journal for ImmunoTherapy of Cancer 2013 1:15

    Published on: 29 August 2013

  15. Research article

    PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody

    Molecular imaging with positron emission tomography (PET) may allow the non-invasive study of the pharmacodynamic effects of agonistic monoclonal antibodies (mAb) to 4-1BB (CD137). 4-1BB is a member of the tum...

    Helena Escuin-Ordinas, Mark W Elliott, Mohammad Atefi, Michelle Lee, Charles Ng, Liu Wei, Begoña Comin-Anduix, Encarnacion Montecino-Rodriguez, Earl Avramis, Caius Radu, Leslie L Sharp and Antoni Ribas

    Journal for ImmunoTherapy of Cancer 2013 1:14

    Published on: 27 August 2013

  16. Short report

    Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb

    Treatment with agonist anti-CD137 (4-1BB) immunostimulatory monoclonal antibodies elicits complete tumor regressions in a number of transplanted hematological and solid malignancies in mice. Rejection is mainl...

    Aizea Morales-Kastresana, Elena Catalán, Sandra Hervás-Stubbs, Asis Palazón, Arantza Azpilikueta, Elixabet Bolaños, Alberto Anel, Julián Pardo and Ignacio Melero

    Journal for ImmunoTherapy of Cancer 2013 1:3

    Published on: 29 May 2013

Previous Page Page 2 of 2 Next Page
JITC logo